HD are-C/HDMTX, high dose cytarabine/high dose methotrexate; COMP, cyclophosphamide, vincristine, methotrexate and prednisolone; Pro MACE-MOPP, Prednisolone, methotrexate, doxorubicin, cyclophosphamide, etoposide/mustine, vincristine, procarbazine and prednisolone; COMET-A, cyclophosphamide, Oncovin, methotrexate, leucovorin, etoposide, cytarabine; COMLA, cyclophosphamide, Oncovin, methotrexate, leucovorin, cytarabine; LNH-84, high-dose methotrexate plus leucovorin, ifosfauride, etoposide, asparaginase, and cytarabine; PVB, prednisolone, vincristine, bleomycin; CEOP, cyclophosphamide, etoposide, vincristine, prednisolone; MACOP-B, methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin; CHVm-p, cyclophosphamide, doxorubicin, teniposide, prednisone, vincristine, bleomycin; EACBOPM-P, etoposide, doxorubicin, cyclophosphamide, bleomycin, vincristine, methotrexate, prednisone

Table of phase II trials with historical controls


Patients treated

Median CD4 count (per mm3)

Complete remission (%)

Median survival (months)

0 0

Post a comment